Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Autologous HER2-specific CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma

NCT04903080 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT04903080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04903080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Autologous HER2-specific CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 27, 2022
Completion date
March 31, 2033
Enrollment
50 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

ependymoma